載入中
InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment specializes in providing electronic ambulatory infusion devices and accompanying disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy facilities. These devices are crucial for managing various cancers, including colorectal cancer, as well as for pain management and other therapeutic needs. Moreover, the company markets, leases, and rents out a selection of new and pre-owned infusion pumps (both pole-mounted and ambulatory) and other vital durable medical equipment. It also sells consumables essential for treatment. InfuSystem further extends its offerings to include biomedical recertification, maintenance, and repair services for oncology practices and diverse alternative care settings, such as home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. Additionally, InfuSystem furnishes both local and field-based customer assistance and manages dedicated pump service and repair facilities. The company was founded in 2005 and maintains its corporate headquarters in Rochester Hills, Michigan.
收盤時
US$13.60
+US$0.04 · +0.29%
盤後
US$13.60
US$0.00 · 0.00%
10月12日 下午4:31 ET
盤中時間採用ET。市場資料可能有所延遲。
InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment specializes in providing electronic ambulatory infusion devices and accompanying disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy facilities. These devices are crucial for managing various cancers, including colorectal cancer, as well as for pain management and other therapeutic needs. Moreover, the company markets, leases, and rents out a selection of new and pre-owned infusion pumps (both pole-mounted and ambulatory) and other vital durable medical equipment. It also sells consumables essential for treatment. InfuSystem further extends its offerings to include biomedical recertification, maintenance, and repair services for oncology practices and diverse alternative care settings, such as home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. Additionally, InfuSystem furnishes both local and field-based customer assistance and manages dedicated pump service and repair facilities. The company was founded in 2005 and maintains its corporate headquarters in Rochester Hills, Michigan.
日內區間
目前US$13.60
52週區間
目前US$13.60
盤中時間採用ET。市場資料可能有所延遲。
InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment specializes in providing electronic ambulatory infusion devices and accompanying disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy facilities. These devices are crucial for managing various cancers, including colorectal cancer, as well as for pain management and other therapeutic needs. Moreover, the company markets, leases, and rents out a selection of new and pre-owned infusion pumps (both pole-mounted and ambulatory) and other vital durable medical equipment. It also sells consumables essential for treatment. InfuSystem further extends its offerings to include biomedical recertification, maintenance, and repair services for oncology practices and diverse alternative care settings, such as home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. Additionally, InfuSystem furnishes both local and field-based customer assistance and manages dedicated pump service and repair facilities. The company was founded in 2005 and maintains its corporate headquarters in Rochester Hills, Michigan.
日內區間
目前US$13.60
52週區間
目前US$13.60
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.43億 USD | 1.35億 USD | 1.26億 USD | 1.1億 USD | 1.02億 USD |
| 銷貨成本 | 6314萬 USD | 6445.8萬 USD | 6267.6萬 USD | 4935.4萬 USD | 4384.6萬 USD |
| 毛利 | 8029.6萬 USD | 7040.3萬 USD | 6310.9萬 USD | 6056萬 USD | 5853.6萬 USD |
| 銷售、一般及管理費用 | 6745.6萬 USD | 6252.1萬 USD | 5803.1萬 USD | 5641.2萬 USD | 5145.4萬 USD |
| 營業費用 | 6837.6萬 USD | 6351.2萬 USD | 5902.1萬 USD | 5890.6萬 USD | 5571.6萬 USD |
| 利息支出 | 129.9萬 USD | 177.7萬 USD | 217萬 USD | 140.2萬 USD | 137.7萬 USD |
| 折舊和攤銷 | 1329.4萬 USD | 1249.9萬 USD | 1250.8萬 USD | 1336萬 USD | 1462.5萬 USD |
| 營業利益 | 1192萬 USD | 689.1萬 USD | 408.8萬 USD | 165.4萬 USD | 282萬 USD |
| 淨利 | 662.7萬 USD | 234.5萬 USD | 87.2萬 USD | 1.8萬 USD | 142萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV1094.19萬0.04%308.51億 USD0.25%US$119.94+0.25%
iShares Russell 2000 ETFIWM665.5萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI664.87萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF288.85萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO244.6萬0.02%139.17億 USD0.24%US$353.71-0.86%
Dimensional - US Small Cap ETFDFAS209.43萬0.01%338.69億 USD0.31%US$78.17-0.23%
Dimensional - US Targeted Value ETFDFAT200.82萬0.01%301.22億 USD0.33%US$67.42+0.22%
Vanguard Russell 2000 ETFVTWO134.86萬0.01%180億 USD0.06%US$112.27-0.35%Avantis U.S. Small Cap Value ETFAVUViShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASDimensional - US Targeted Value ETFDFATVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
